Capitolis Liquid Global Markets LLC Has $48.46 Million Stock Position in Merck & Co., Inc. $MRK

Posted by Brian Himes on Jun 18th, 2026

Capitolis Liquid Global Markets LLC grew its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 81.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 460,400 shares of the company’s stock after buying an additional 206,700 shares during the period. Capitolis Liquid Global Markets LLC’s holdings in Merck & Co., Inc. were worth $48,462,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $31,000. Finally, High Note Wealth LLC increased its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 0.4%

NYSE:MRK opened at $115.67 on Thursday. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $285.69 billion, a P/E ratio of 32.58, a P/E/G ratio of 2.59 and a beta of 0.21. The stock’s fifty day simple moving average is $116.22 and its 200-day simple moving average is $113.53.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company earned $2.22 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Analyst Ratings Changes

MRK has been the subject of several research reports. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Get Our Latest Research Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.